UNSPSC 51333415: Ziprasidone hydrochloride monohydrate

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone monohydrochloride, monohydrate but more generally known as ziprasidone hydrochloride, which bears US NIH Compound Identifier 60853.

European Medicines Agency schedules Ziprasidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05189MIG. Most nations, for tariff and trade purposes, schedule ziprasidone hydrochloride monohydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.

UNSPSC 51333415 Ziprasidone hydrochloride monohydrate is a Commodity code that shows minimal recent activity aligned with its nominal scope. The three most recent state and local opportunities tagged to this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program, and generic multi-source pharmaceuticals and OTC products — none of which directly address ziprasidone hydrochloride monohydrate, an atypical antipsychotic medication. The mismatch suggests either miscoding at the issuing body level or that this Commodity code does not reflect current state and local procurement patterns for the specific active pharmaceutical ingredient it nominally describes.

The issuing bodies span a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, covering Minnesota and Oregon). The Seminole County IFB posted June 30, 2026, with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS RFI posted April 3, 2026, explores direct-to-manufacturer prescription capabilities; and the MMCAP RFP posted January 20, 2026, with response due March 26, 2026, establishes contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. Geographic activity clusters in Florida, Texas, Minnesota, and Oregon, though the opportunities do not support characterization of ziprasidone hydrochloride monohydrate procurement patterns. No recent opportunities appear to solicit this Commodity code for its intended scope.